You are viewing the site in preview mode

Skip to main content

Advertisement

Figure 4 | Journal for ImmunoTherapy of Cancer

Figure 4

From: iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine

Figure 4

Combined OVA/CpG vaccine and CD1d-antitumor fusion lead to enhanced antitumor effects correlating with accumulation of OVA-specific CTLs at the tumor site. Recipient CD45.1 mice were grafted s.c. with B16-OVA-HER2 tumor cells following Vα14-Jα18 and OT-I transfer and 5 days later, they were immunized and treated as described in Figure 1 and in the Methods. A. Kinetic of tumor growth shown as mean tumor volume (mm3) +/- SEM of 5 mice/group. B-C. Mice were sacrificed 7 days after the immunisation and B, frequency of H-2Kb/OVA-specific CD8 T cells among total tumor infiltrating CD8 T lymphocytes and C, frequency of NK cells among total tumor lymphocytes were measured. Bar graphs show frequencies as mean +/- SEM of groups of 3 mice. Data are representative of 3 independent experiments. *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.

Back to article page